<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38028066</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-0904</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical case reports</Title><ISOAbbreviation>Clin Case Rep</ISOAbbreviation></Journal><ArticleTitle>Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review.</ArticleTitle><Pagination><StartPage>e8162</StartPage><MedlinePgn>e8162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e8162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccr3.8162</ELocationID><Abstract><AbstractText Label="KEY CLINICAL MESSAGE" NlmCategory="UNASSIGNED">Findings here imply lingering of virus, SARS-CoV-2, in the body for months. Thus, Nitazoxanide and/or other anti-viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally.</AbstractText><AbstractText Label="ABSTRACT" NlmCategory="UNASSIGNED">Long COVID or post-acute sequelae of COVID-19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well-known, safe anti-viral medications use against PASC is proposed here.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Clinical Case Reports published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Denise D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0003-1984-3430</Identifier><AffiliationInfo><Affiliation>Department of Life Sciences Imperial College London London UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Case Rep</MedlineTA><NlmUniqueID>101620385</NlmUniqueID><ISSNLinking>2050-0904</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">Nitazoxanide</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">acyclovir</Keyword><Keyword MajorTopicYN="N">anti&#x2010;viral medication</Keyword><Keyword MajorTopicYN="N">herpesviruses</Keyword><Keyword MajorTopicYN="N">latent virus reactivation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post&#x2010;acute sequelae (PASC)</Keyword><Keyword MajorTopicYN="N">shingles</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38028066</ArticleId><ArticleId IdType="pmc">PMC10654558</ArticleId><ArticleId IdType="doi">10.1002/ccr3.8162</ArticleId><ArticleId IdType="pii">CCR38162</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Rev Microbiol. 2023;21:133&#x2010;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post&#x2010;acute sequelae of COVID&#x2010;19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15:869&#x2010;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et&#xa0;al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27:601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokhande AS, Devarajan PV. A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID&#x2010;19. Eur J Phar. 2021;891:173748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678434</ArticleId><ArticleId IdType="pubmed">33227285</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuo&#x2010;Rahma GEA, Mohamed MFA, Ibrahim TS. Potential repurposed SARS&#x2010;CoV&#x2010;2 (COVID&#x2010;19) infection drugs. RSC Adv. 2020;10:26895&#x2010;26916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9055522</ArticleId><ArticleId IdType="pubmed">35515773</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar H, Montovano M, Banada P, et&#xa0;al. RT&#x2010;PCR negative COVID&#x2010;19. BMC Infect Dis. 2022;22(149):149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841043</ArticleId><ArticleId IdType="pubmed">35152885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false&#x2010;negative rate of reverse transcriptase polymerase chain reaction&#x2013;based SARS&#x2010;CoV&#x2010;2 tests by time since exposure. Ann Intern Med. 2020;5:M20&#x2010;M1495. doi:10.7326/M20-1495</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1495</ArticleId><ArticleId IdType="pmc">PMC7240870</ArticleId><ArticleId IdType="pubmed">32422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Yang M, Yuan J, et&#xa0;al. Laboratory diagnosis and monitoring the viral shedding of SARS&#x2010;CoV&#x2010;2 infection. Innovation. 2020;1:100061. doi:10.1016/j.xinn.2020.100061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xinn.2020.100061</ArticleId><ArticleId IdType="pmc">PMC7609236</ArticleId><ArticleId IdType="pubmed">33169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et&#xa0;al. Evolution of antibody immunity to SARS&#x2010;CoV&#x2010;2. Nature. 2021;591:639&#x2010;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Morone G, Palomba A, Iosa M, et&#xa0;al. Incidence and persistence of viral shedding in COVID&#x2010;19 post&#x2010;acute patients with negativized pharyngeal swab: a systematic review. Front Med. 2020;7:562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483760</ArticleId><ArticleId IdType="pubmed">32984389</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsena SSF, Pahus MH, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 persistence is associated with antigen&#x2010;specific CD8+ T&#x2010;cell responses. EBioMedicine. 2021;64:103230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2010;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajnzylber J, Regan J, Coxen K, et&#xa0;al. Massachusetts consortium for pathogen readiness. SARS&#x2010;CoV&#x2010;2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Meyer B, Eckerle I. SARS&#x2010;CoV&#x2010;2 viral load and shedding kinetics. Nature Rev Microbiol. 2023;21:147&#x2010;161. doi:10.1038/s41579-022-00822-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00822-w</ArticleId><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Nirula A, Heller b, et&#xa0;al. SARSCoV&#x2010;2 neutralizing antibody LY&#x2010;CoV555 in outpatients with Covid&#x2010;19. N Engl J Med. 2021;384:229&#x2010;237. doi:10.1056/NEJMoa2029849</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2029849</ArticleId><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et&#xa0;al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell. 2022;185:881&#x2010;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Guo C, Tang L, et&#xa0;al. Prolonged presence of SARS&#x2010;CoV&#x2010;2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;5:434&#x2010;435. doi:10.1016/S2468-1253(20)30083-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30083-2</ArticleId><ArticleId IdType="pmc">PMC7158584</ArticleId><ArticleId IdType="pubmed">32199469</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et&#xa0;al. Gastrointestinal symptoms and fecal shedding of SARS&#x2010;CoV&#x2010;2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371&#x2010;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA. A negative COVID&#x2010;19 test does not mean recovery. Nature. 2020;584:170.</Citation><ArticleIdList><ArticleId IdType="pubmed">32782377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Cai Z, Wu W, et&#xa0;al. The novel coronavirus (COVID&#x2010;19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case report. BMC Infect Dis. 2020;20:317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191555</ArticleId><ArticleId IdType="pubmed">32354369</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019&#x2010;nCoV pneumonia: relationship to negative RT&#x2010;PCR testing. Radiology. 2020;296:E41&#x2010;E45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233363</ArticleId><ArticleId IdType="pubmed">32049601</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et&#xa0;al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease&#x2010;2019 (COVID&#x2010;19). Nat Comms. 2021;12:267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanji JN, Zelyas N, MacDonald C, et&#xa0;al. False negative rate of COVID&#x2010;19 PCR testing: a discordant testing analysis. Virol J. 2021;18:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794619</ArticleId><ArticleId IdType="pubmed">33422083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossignol JF. Nitazoxanide: a first in&#x2010;class broad&#x2010;spectrum antiviral agent. Antiviral Res. 2014;110:94&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113776</ArticleId><ArticleId IdType="pubmed">25108173</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachulski AV, Taujanskas J, Pate SL, et&#xa0;al. Therapeutic potential of Nitazoxanide: an appropriate choice for repurposing versus SARS&#x2010;CoV&#x2010;2? ACS Infect Dis. 2021;7(6):1317&#x2010;1331. doi:10.1021/acsinfecdis.0c00478</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00478</ArticleId><ArticleId IdType="pubmed">33352056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227&#x2010;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102735</ArticleId><ArticleId IdType="pubmed">27095301</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccio A, Santopolo S, Rossi A, Piacentini S, Rossignol JF, Santoro MG. Impairment of SARS&#x2010;CoV&#x2010;2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. Cell Mol Life Sci. 2022;79:227. doi:10.1007/s00018-022-04246-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04246-w</ArticleId><ArticleId IdType="pmc">PMC8989121</ArticleId><ArticleId IdType="pubmed">35391601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Forrest JC, Zhang X. A screen of the NIH clinical collection small molecule library identifies potential anti&#x2010;coronavirus drugs. Antiviral Res. 2015;114:1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113785</ArticleId><ArticleId IdType="pubmed">25451075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, et&#xa0;al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x2010;nCoV) in&#xa0;vitro. Cell Res. 2020;30:269&#x2010;271. doi:10.1038/s41422-020-0282-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS&#x2010;CoV&#x2010;2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin L, Mire CE, Ranjbar S, et&#xa0;al. The oral drug nitazoxanide restricts SARS&#x2010;CoV&#x2010;2 infection and attenuates disease pathogenesis in Syrian hamsters. bioRxiv. 2022. doi:10.1101/2022.02.08.479634</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.08.479634</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;kuraishy HM, Al&#x2010;Gareeb AI, Elekhnawy E, Batiha EG. Nitazoxanide and COVID&#x2010;19: a review. Mol Biol Rep. 2022;49:11169&#x2010;11176. doi:10.1007/s11033-022-07822-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07822-2</ArticleId><ArticleId IdType="pmc">PMC9465141</ArticleId><ArticleId IdType="pubmed">36094778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei S, Chen X, Wu J, Duan X, Men K. Small molecules in the treatment of COVID&#x2010;19. Signal Transduct Target Ther. 2022;7:387. doi:10.1038/s41392-022-01249-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01249-8</ArticleId><ArticleId IdType="pmc">PMC9719906</ArticleId><ArticleId IdType="pubmed">36464706</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum VF, Cimerman S, Hunter JR, et&#xa0;al. Nitazoxanide superiority to placebo to treat moderate COVID&#x2010;19 &#x2013;a pilot prove of concept randomized double&#x2010;blind clinical trial. EClinicalMedicine. 2021;37:100981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8235996</ArticleId><ArticleId IdType="pubmed">34222847</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n JM, Flores MDRF, Coria LP, et&#xa0;al. Nitazoxanide against COVID&#x2010;19 in three explorative scenarios. J Infect Dev Ctries. 2020;14(9):982&#x2010;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">33031085</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocco PRM, Silva PL, Cruz FF, et&#xa0;al. Early use of nitazoxanide in mild COVID&#x2010;19 disease: randomised, placebo&#x2010;controlled trial. Eur Respir J. 2021;58:2003725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758778</ArticleId><ArticleId IdType="pubmed">33361100</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Br&#xe9;chot C, for the Vanguard Study Group . A randomized double&#x2010;blind placebo&#x2010;controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID&#x2010;19. EClinicalMedicine. 2022;45:101310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883002</ArticleId><ArticleId IdType="pubmed">35237748</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocco P, Silva P, Cruz FF, et&#xa0;al. Nitazoxanide in patients hospitalized with COVID&#x2010;19 pneumonia: a multicentre, randomized, double&#x2010;blind, Placebo&#x2010;Controlled Trial. Front Med. 2022;9:844728. doi:10.3389/fmed.2022.844728</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.844728</ArticleId><ArticleId IdType="pmc">PMC9043450</ArticleId><ArticleId IdType="pubmed">35492335</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon JM, Padmanabhan S, Salazar FMC, et&#xa0;al. Treatment with hydroxychloroquine vs nitazoxanide in patients with COVID&#x2010;19: brief report. PAMJ Clin Med. 2021;7(15):1&#x2010;11.</Citation></Reference><Reference><Citation>Zeron MH, Calderon MJ, Coria LP, et&#xa0;al. Nitazoxanide as an early treatment to reduce the intensity of COVID&#x2010;19 outbreaks among health personnel. World Acad Sci J. 2021;3:1&#x2010;6.</Citation></Reference><Reference><Citation>Medhat MA, El&#x2010;Kassas M, Karam&#x2010;Allah H, et&#xa0;al. Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID&#x2010;19 infection: a randomized controlled trial for repurposing antivirals. Arab J Gastroenterol. 2022;23(3):165&#x2010;171. doi:10.1016/j.ajg.2022.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajg.2022.04.005</ArticleId><ArticleId IdType="pmc">PMC9116423</ArticleId><ArticleId IdType="pubmed">35690556</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero&#x2010;Cabello R, Romero&#x2010;Feregrino R, Romero&#x2010;Feregrino R, Mu&#xf1;oz&#x2010;Cordero B, Sevilla&#x2010;Fuentes S. Outpatient treatment of COVID&#x2010;19: an experience with 552 cases in Mexico. J Infect Dev Ctries. 2023;17(3):311&#x2010;318. doi:10.3855/jidc.16982</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.16982</ArticleId><ArticleId IdType="pubmed">37023433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni MT. The African Kelleni's roadmap using nitazoxanide and broad&#x2010;spectrum antimicrobials to abort returning to COVID&#x2010;19 square one. Inflammopharmacology. 2023. doi:10.1007/s10787-023-01263-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01263-4</ArticleId><ArticleId IdType="pmc">PMC10691980</ArticleId><ArticleId IdType="pubmed">37326756</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell LB, Alcolea&#x2010;Medina A, Charalampous T, et&#xa0;al. Real&#x2010;time whole genome sequencing to guide patient&#x2010;tailored therapy of severe acute respiratory syndrome coronavirus 2 Infection. Clin Infect Dis. 2022;15(6):1125&#x2010;1128. doi:10.1093/cid/ciac864</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac864</ArticleId><ArticleId IdType="pmc">PMC10029986</ArticleId><ArticleId IdType="pubmed">36327795</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir&#x2010;ritonavir: Oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis. 2023;76(1):165&#x2010;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383515</ArticleId><ArticleId IdType="pubmed">35245942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister&#x2010;Tebbe H, Gardner A, et&#xa0;al. EPIC&#x2010;HR investigators. Oral nirmatrelvir for high&#x2010;risk, nonhospitalized adults with COVID&#x2010;19. N Engl J Med. 2022;386(15):1397&#x2010;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Allerton CMN, Anderson AS, et&#xa0;al. An oral SARS&#x2010;CoV&#x2010;2 M(pro) inhibitor clinical candidate for the treatment of COVID&#x2010;19. Science. 2021;374:1586&#x2010;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir boosted protease inhibitor therapy in HIV infected patients. J Antimicrob Chemother. 2004;53(1):4&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14657084</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et&#xa0;al. Remdesivir for the treatment of COV1D&#x2010;19: final report. N Engl J Med. 2020;383:1813&#x2010;1826. doi:10.1056/NEJMoa2007764</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JA, Gomes da Silva MM, Musungaie DB, et&#xa0;al. Molnupiravir for oral treatment of COVID&#x2010;19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509&#x2010;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, Hobbs FDR, Gbinigie OA, et&#xa0;al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID&#x2010;19 at increased risk of adverse outcomes (PANORAMIC): an open&#x2010;label, platform adaptive randomised controlled trial. Lancet. 2023;401:281&#x2010;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Arribas JR, Bhagani S, Lobo SM, Khaertynova I, et&#xa0;al. Randomized trial of Molnupiravir or placebo in patients hospitalized with COVID&#x2010;19. NEJM Evid. 2022;1(2):1&#x2010;13. doi:10.1056/EVIDoa2100044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2100044</ArticleId><ArticleId IdType="pubmed">38319178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang D, Du G, et&#xa0;al. Remdesivir in adults with severe COVID&#x2010;19: a randomised, double&#x2010;blind, placebo&#x2010;controlled, multicentre trial. Lancet. 2020;395:1569&#x2010;1578. doi:10.1016/S0140-736(20)31022-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium . Repurposed antiviral drugs for Covid&#x2010;19 &#x2014;interim WHO solidarity trial results. N Engl J Med. 2021;384:497&#x2010;511. doi:10.1056/NEJMoa2023184</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner CD, Gottlieb RL, Criner GJ, et&#xa0;al. Effect of Remdesivir vs standard care on clinical status at 11&#x2009;days in patients with moderate COVID&#x2010;19. A randomized clinical trial. JAMA. 2020;324(11):1048&#x2010;1057. doi:10.1001/jama.2020.16349</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B, Green ACA, Tazare J, et&#xa0;al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid&#x2010;19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ. 2022;379:e071932. doi:10.1136/bmj-2022-071932</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071932</ArticleId><ArticleId IdType="pmc">PMC9667468</ArticleId><ArticleId IdType="pubmed">36384890</ArticleId></ArticleIdList></Reference><Reference><Citation>Guermazi D, Arvanitis P, Farmakiotis D. Molnupiravir efficacy among immunocompromised patients with COVID&#x2010;19: no proof of concept. Infection. 2023;51:1593&#x2010;1595. doi:10.1007/s15010-023-02027-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02027-6</ArticleId><ArticleId IdType="pmc">PMC10066965</ArticleId><ArticleId IdType="pubmed">37004695</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer A, Martinez DR, Won JJ, et&#xa0;al. Therapeutic treatment with oral prodrug of the Remdesivir parental nucleoside is protective against SARS&#x2010;CoV&#x2010;2 pathogenesis in mice. Sci Transl Med. 2022;14(643):eabm3410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995034</ArticleId><ArticleId IdType="pubmed">35315683</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashita E, Yamayoshi S, Simon V, et&#xa0;al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468&#x2010;470. doi:10.1056/NEJMc2207519</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2207519</ArticleId><ArticleId IdType="pmc">PMC9342381</ArticleId><ArticleId IdType="pubmed">35857646</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters HA, Jochmans D, de Wilde AH, et&#xa0;al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti&#x2010;coronavirus activity. Bioorg Med Chem Lett. 2015;25:2923&#x2010;2926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466200</ArticleId><ArticleId IdType="pubmed">26048809</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos IA, Grosche VR, Bergamini FRG, Sabino&#x2010;Silva R, Jardim ACG. Antivirals against coronaviruses: candidate drugs for SARS&#x2010;CoV&#x2010;2 treatment? Front Microbiol. 2020;11:1818. doi:10.3389/fmicb.2020.01818</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01818</ArticleId><ArticleId IdType="pmc">PMC7438404</ArticleId><ArticleId IdType="pubmed">32903349</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker VS. Acyclovir for SARS&#x2010;CoV&#x2010;2: an old drug with a new purpose. Clin Pract. 2021;18(1):1584&#x2010;1592.</Citation></Reference><Reference><Citation>Baker VS. ACYCLOVIR for SARS&#x2010;CoV&#x2010;2: an old drug with a new therapeutic purpose&#x2014;an observational study. Int J Clin Case Rep Rev. 2022;10(2):1&#x2010;7. doi:10.31579/2690-4861/199</Citation><ArticleIdList><ArticleId IdType="doi">10.31579/2690-4861/199</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewska A, Mlynarczyk&#x2010;Bonikowska B. 40&#x2009;years after the registration of acyclovir: do we need new anti&#x2010;herpetic drugs? Int J Mol Sci. 2022;23:3431. doi:10.3390/ijms23073431</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073431</ArticleId><ArticleId IdType="pmc">PMC8998721</ArticleId><ArticleId IdType="pubmed">35408788</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Ishii KK, Zuccola H, et&#xa0;al. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of a&#x2010;like DNA polymerases. Proc Natl Acad Sci USA. 1999;96:447&#x2010;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15156</ArticleId><ArticleId IdType="pubmed">9892653</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Yang L. Underlying mechanisms and candidate drugs for covid&#x2010;19 based on the connectivity map database. Front Genet. 2020;11:558557. doi:10.3389/fgene.2020.558557</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.558557</ArticleId><ArticleId IdType="pmc">PMC7652993</ArticleId><ArticleId IdType="pubmed">33193639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Kumari K, Bahadur I, Singh P. Promising acyclovir and its derivatives to inhibit the protease of SARS&#x2010;CoV&#x2010;2: molecular docking and molecular dynamics simulations. Res Sq. preprint. doi:10.21203/rs.3.rs-94864/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-94864/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Far BF, Bokov D, Widjaja G, et&#xa0;al. Metronidazole, acyclovir and tetrahydrobiopterin may be promising to treat COVID&#x2010;19 patients, through interaction with interleukin&#x2010;12. J Biomol Struct Dyn. 2022;21:1&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">35446232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavsar A, Lonnet G, Wang C, et&#xa0;al. Increased risk of herpes zoster in adults &#x2265;50&#x2009;years old diagnosed with COVID&#x2010;19 in the United States. Open Forum Infect Dis. 2022;9(5):ofac118. doi:10.1093/ofid/ofac118</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac118</ArticleId><ArticleId IdType="pmc">PMC8982770</ArticleId><ArticleId IdType="pubmed">35392454</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidary F, Madani S, Gharebaghi R, Asadi&#x2010;Amoli F. Acyclovir as a potential add&#x2010;on therapy in COVID&#x2010;19 treatment regimens. Pharm Sci. 2021;27(Suppl 1):S68&#x2010;S77. doi:10.34172/PS.2021.38</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/PS.2021.38</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Nie J, Wang H, et&#xa0;al. Characteristics of peripheral lymphocyte subset alteration in COVID&#x2010;19 pneumonia. J Infect Dis. 2020;221:1762&#x2010;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184346</ArticleId><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID prevalence and its relationship to Epstein&#x2010;Barr virus reactivation. Pathogens. 2021;10(6):763. doi:10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobbe DR, Di Bella S, Lovecchio A, et&#xa0;al. Herpes simplex virus 1 (HSV&#x2010;1) reactivation in critically ill COVID&#x2010;19 patients: a brief narrative review. Infect Dis Ther. 2022;11:1779&#x2010;1791. doi:10.1007/s40121-022-00674-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00674-0</ArticleId><ArticleId IdType="pmc">PMC9340740</ArticleId><ArticleId IdType="pubmed">35913679</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini ML, Pruijssers AJ, Chappell JD, et&#xa0;al. Small&#x2010;molecule antiviral beta&#x2010;d&#x2010;N (4)&#x2010;Hydroxycytidine inhibits a proofreading&#x2010;intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880162</ArticleId><ArticleId IdType="pubmed">31578288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Klein J, Robertson AJ, et&#xa0;al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS&#x2010;CoV&#x2010;2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13:1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan JI, Duerr R, Dimartino D, et&#xa0;al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019 (COVID&#x2010;19). Clin Infect Dis. 2023;76(2):342&#x2010;345. doi:10.1093/cid/ciac769</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac769</ArticleId><ArticleId IdType="pmc">PMC9619446</ArticleId><ArticleId IdType="pubmed">36156117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjaarda CP, Lau L, Simpson JT, et&#xa0;al. Prevalence of low&#x2010;frequency, antiviral resistance variants in SARS&#x2010;CoV&#x2010;2 isolates in Ontario, Canada, 2020&#x2013;2023. JAMA Netw Open. 2023;6(7):e2324963. doi:10.1001/jamanetworkopen.2023.24963</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.24963</ArticleId><ArticleId IdType="pmc">PMC10362469</ArticleId><ArticleId IdType="pubmed">37477915</ArticleId></ArticleIdList></Reference><Reference><Citation>Service, R. F . Bad news for Paxlovid? Resistance may be coming. Science. 2022;377:138&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">35857562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilmanis D, Koszalka P, Barr IG, Rossignol JF, Mifsud E, Hurt AC. Host&#x2010;targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir&#x2010;resistant influenza viruses in&#xa0;vitro or in&#xa0;vivo when used in combination with oseltamivir. Antiviral Res. 2020;180:104851. doi:10.1016/j.antiviral.2020.104851</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104851</ArticleId><ArticleId IdType="pubmed">32544408</ArticleId></ArticleIdList></Reference><Reference><Citation>

 https://www.drugs.com/drug&#x2010;interactions/nitazoxanide,alinia.html#</Citation></Reference><Reference><Citation>Vets E, Rossignol JF, Jackson AS. Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health&#x2010;Syst Pharm. 2009;66(5):838&#x2010;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">19386947</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullokandov E, Ahn J, Szalkiewicz A, Babayeva M. Protein binding drug&#x2010;drug interaction between warfarin and Tizoxanide in human plasma. Austin J Pharmacol Ther. 2014;2(7):1038.</Citation></Reference><Reference><Citation>Clemente NS, Penner J, Breuer J, Ip W, Booth C. Case report: a severe Paediatric Presentation of COVID&#x2010;19 in APDS2 immunodeficiency. Front Immunol. 2022;13:881259. doi:10.3389/fimmu.2022.881259</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.881259</ArticleId><ArticleId IdType="pmc">PMC9190774</ArticleId><ArticleId IdType="pubmed">35707532</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>